PubHawk
JCO Precis Oncol July 2023 PMID 37410975

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.

Julia C F Quintanilha, Michael H Storandt, Ryon P Graf, Gerald Li, Rachel Keller, Douglas I Lin, Jeffrey S Ross, Richard S P Huang, Alexa B Schrock, Geoffrey R Oxnard, Sakti Chakrabarti, Amit Mahipal

Full text PDF Download social card

Mentions

37
Peak: 27 in Jul 2023
across 2 sources since Jul 2023

Extended reach

207,715
potential audience

Total likes

168

Video views

32

Mentions per month

Jul 2023 – Feb 2025

Where it's discussed

  • X / Twitter36 posts
  • YouTube1 videos

AI synopsis

What people are saying

The discussions highlight the importance of the research by referencing statistics such as only 1.3% of pancreatic cancer patients having high TMB, emphasizing its potential for improving immunotherapy responses. The tone across posts is analytical and cautiously optimistic, often mentioning the 'transformative' potential of identifying biomarkers like TMB, though some posts also express skepticism about its immediate clinical impact because of the low prevalence.

AgreementModerate agreement

Most discussions acknowledge the findings, especially noting the rarity of high TMB in pancreatic cancer but its significance for immunotherapy response.

InterestHigh interest

Posts show high curiosity, with many discussing the potential of high TMB as a biomarker and exploring its implications for treatment options.

EngagementModerate engagement

Several social discussions mention specific details like the 1.3% prevalence and improved survival rates, indicating moderate to deep engagement.

ImpactModerate impact

While some posts recognize the importance of this research in expanding treatment possibilities, the overall perception is that its impact is notable but limited currently due to the rarity of high TMB cases.

Abstract in brief

  • PDAC is typically nonimmunogenic, but about 1% of patients exhibit high tumor mutational burden (TMB) or other alterations that could indicate a better response to immune checkpoint inhibitors (ICI).
  • In a study of 21,932 PDAC patients, only 1.3% showed high-TMB, with associated genomic alterations differing based on TMB levels.
  • Patients with high-TMB who received ICI therapy had significantly improved overall survival compared to those with low-TMB, highlighting the potential of high-TMB as a biomarker for ICI therapy efficacy in PDAC.
Read the full abstract

Top posts

Most liked on X and Bluesky
alex rubinsteyn
@iskander · X

...and what does high TMB mean in PDAC (like in many other cancers)? That's right, better response to checkpoint blockade (https://t.co/tTiGteNDZ0) -- see the dose of atezolizumab at week 6.

Feb 27, 2025 · 83 likes · 1 share · 6,272 followers View post →
Anirban Maitra
@Aiims1742 · X

#OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness https://t.co/WPbRJ1G7jl Most telling data (not unexpected) is how https://t.co/yfp682gWss

Jul 6, 2023 · 33 likes · 16 shares · 31,463 followers View post →
レ点
@m0370 · X

膵癌でがん遺伝子パネル検査を受けた2.2万人という途方もない規模のデータ…（ちなみに全がん種合計の日本のC-CATで今4万人台？）。その内TMB-Hはわずか293人（1.3%）、ICIを投与されたのはたった51人…

Jul 19, 2023 · 29 likes · 3 shares · 28,876 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Aug 11, 2023 · 14 likes · 6 shares · 5,307 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Jul 14, 2023 · 6 likes · 3 shares · 5,307 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Tumor Mutational Burden in Real-world Patients with #PancreaticCancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness

Jul 27, 2023 · 2 likes · 2 shares · 5,307 followers View post →

All mentions

alex rubinsteyn
@iskander · X

...and what does high TMB mean in PDAC (like in many other cancers)? That's right, better response to checkpoint blockade (https://t.co/tTiGteNDZ0) -- see the dose of atezolizumab at week 6.

Feb 27, 2025 · 83 likes · 1 share · 6,272 followers View post →
Lesley Goodburn
@lgoodbu · X

RT @perilonthesea: Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immu…

Aug 21, 2023 · 1 share · 6,062 followers View post →
SJPurplePurpose
@SJPurplePurpose · X

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness https://t.co/u4ZhGF9DTR

Aug 21, 2023 · 1 like · 1 share · 1,363 followers View post →
Pat Adams
@PathologyPat · X

RT @JCOPO_ASCO:

Aug 11, 2023 · 6 shares · 1,515 followers View post →
Luis Arturo Cardoso Aparicio
@lacamustang · X

RT @JCOPO_ASCO:

Aug 11, 2023 · 6 shares · 272 followers View post →
Christine Lovly, MD, PhD, FASCO
@christine_lovly · X

RT @JCOPO_ASCO:

Aug 11, 2023 · 6 shares · 7,901 followers View post →
Geoff Oxnard MD
@geoff_oxnard · X

RT @JCOPO_ASCO:

Aug 11, 2023 · 6 shares · 4,001 followers View post →
Dr. Poetic
@Dr_Doc_ · X

RT @JCOPO_ASCO:

Aug 11, 2023 · 6 shares · 3,033 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Aug 11, 2023 · 14 likes · 6 shares · 5,307 followers View post →
Geoff Oxnard MD
@geoff_oxnard · X

RT @JCOPO_ASCO: Tumor Mutational Burden in Real-world Patients with #PancreaticCancer: Genomic Alterations and Predictive Value for Immune…

Jul 27, 2023 · 2 shares · 4,001 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Tumor Mutational Burden in Real-world Patients with #PancreaticCancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness

Jul 27, 2023 · 2 likes · 2 shares · 5,307 followers View post →
Cancer_Evolve
@cancer_evolve · X

PANCREAS: in a large adenocarcinoma cohort (n= 21,932), high tumour mutation burden (≥10 mutations/Mb) was present in 1.3% of cases (of whom a third were MSI+) and associated with enhanced response to immune checkpoint inhibition (OS 26 vs 5 months). https://t.co/zJn6f2gCqB

Jul 20, 2023 · 370 followers View post →
義一YOSHIKAZU.YOSHIKAZU零
@5Iu0cZWla0sxrni · X

RT @m0370: 膵癌でがん遺伝子パネル検査を受けた2.2万人という途方もない規模のデータ…（ちなみに全がん種合計の日本のC-CATで今4万人台？）。その内TMB-Hはわずか293人（1.3%）、ICIを投与されたのはたった51人…

Jul 19, 2023 · 3 shares · 5,606 followers View post →
уон
@yoh_tw · X

RT @m0370: 膵癌でがん遺伝子パネル検査を受けた2.2万人という途方もない規模のデータ…（ちなみに全がん種合計の日本のC-CATで今4万人台？）。その内TMB-Hはわずか293人（1.3%）、ICIを投与されたのはたった51人…

Jul 19, 2023 · 3 shares · 281 followers View post →
Dr.マローウ（プリンじゃない方）
@DrBMLNMMML · X

RT @m0370: 膵癌でがん遺伝子パネル検査を受けた2.2万人という途方もない規模のデータ…（ちなみに全がん種合計の日本のC-CATで今4万人台？）。その内TMB-Hはわずか293人（1.3%）、ICIを投与されたのはたった51人…

Jul 19, 2023 · 3 shares · 1,724 followers View post →
レ点
@m0370 · X

膵癌でがん遺伝子パネル検査を受けた2.2万人という途方もない規模のデータ…（ちなみに全がん種合計の日本のC-CATで今4万人台？）。その内TMB-Hはわずか293人（1.3%）、ICIを投与されたのはたった51人…

Jul 19, 2023 · 29 likes · 3 shares · 28,876 followers View post →
Mark Fortner
@phidias51 · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 17, 2023 · 16 shares · 694 followers View post →
Foundation Medicine
@FoundationATCG · X

RT @JCOPO_ASCO:

Jul 14, 2023 · 3 shares · 9,813 followers View post →
Geoff Oxnard MD
@geoff_oxnard · X

RT @JCOPO_ASCO:

Jul 14, 2023 · 3 shares · 4,001 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Jul 14, 2023 · 6 likes · 3 shares · 5,307 followers View post →
Dr. Edna Cukierman, Ph.D.
@ednacukierman · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 13, 2023 · 16 shares · 4,200 followers View post →
SJPurplePurpose
@SJPurplePurpose · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 12, 2023 · 16 shares · 1,363 followers View post →
Yang Chen
@YangChenPhD · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 7, 2023 · 16 shares · 740 followers View post →
Eduardo Terán
@EduardoTB94 · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 7, 2023 · 16 shares · 461 followers View post →
Geoff Oxnard MD
@geoff_oxnard · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 7, 2023 · 16 shares · 4,001 followers View post →
Ben Westphalen
@BenWestphalen · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 7, 2023 · 16 shares · 5,034 followers View post →
OncoAlert
@OncoAlert · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 7, 2023 · 16 shares · 40,054 followers View post →
Donatella Delle Cave
@DonatellaCave · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 7, 2023 · 16 shares · 309 followers View post →
Xiuli Liu
@XiuliLiu1 · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 6, 2023 · 16 shares · 427 followers View post →
Aatur Singhi, MD PhD
@PancPathologist · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 6, 2023 · 16 shares · 7,534 followers View post →
Let's Win Pancreatic Cancer
@letswinpc · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 6, 2023 · 16 shares · 8,053 followers View post →
Immuno-Oncology
@immuno_onc · X

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness https://t.co/xkiiBaoFU3 https://t.co/Pym6itYNOJ

Jul 6, 2023 · 115 followers View post →
4baseCare
@4baseCare · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 6, 2023 · 16 shares · 396 followers View post →
Mike Cane
@mikecane · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 6, 2023 · 16 shares · 989 followers View post →
Avishek Roy
@Aviavipshaapal · X

RT @Aiims1742: #OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Geno…

Jul 6, 2023 · 16 shares · 199 followers View post →
Anirban Maitra
@Aiims1742 · X

#OpenAccess in @JCOPO_ASCO from @FoundationATCG Tumor Mutational Burden in Real-World Patients With #PancreaticCancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness https://t.co/WPbRJ1G7jl Most telling data (not unexpected) is how https://t.co/yfp682gWss

Jul 6, 2023 · 33 likes · 16 shares · 31,463 followers View post →